RecoveryEvidence-BasedAug 2026

Best Peptides for Arthritis in 2026

The published studies behind peptides investigated in arthritis, one row per study, with the population enrolled, the endpoint measured, the number reported and the PubMed identifier. They span rheumatoid arthritis, knee osteoarthritis, cartilage imaging and joint surgery recovery. Arthritis is diagnosed and managed with a doctor, and everything below describes research rather than recommending treatment.

407

Adults with obesity and knee osteoarthritis in the 68-week semaglutide trial (PMID 39476339)

154

Adults randomised to the double-blind withdrawal period of the corticotropin trial (PMID 32185745)

0.05 mm

Cartilage thickness against placebo at 2 years, one arm of the 549-person sprifermin trial (PMID 31593273)

Read this first

Care comes from a clinician. Rheumatoid arthritis and osteoarthritis are diagnosed and managed by a doctor, and untreated inflammatory arthritis damages joints. Repository corticotropin injection is approved in the United States as adjunctive therapy for short-term administration in patients with continued rheumatoid arthritis disease activity (Fleischmann and Furst, Expert Opin Drug Saf 2020, PMID 32497440). A 2025 systematic review records BPC-157 as an unapproved substance under the United States Food and Drug Administration and prohibited in professional sport (Vasireddi et al., HSS J 2025, PMID 40756949).

The studies

One row per study, and a compound with several studies has several rows. Read the population column first.

Compound	Population (n)	What was measured	Result	Design	PMID
Repository corticotropin injection	154 adults with rheumatoid arthritis who reached low disease activity on 12 weeks of open-label treatment, 77 randomised per arm	Maintaining low disease activity (DAS28-ESR under 3.2) at week 24, a secondary endpoint	61.0 against 42.1 percent on placebo, p = 0.019	Randomised double-blind withdrawal	32185745
dnaJP1 (oral tolerising peptide)	160 adults with active rheumatoid arthritis, reactive to dnaJP1	ACR20 on day 112, 140 or 168	Group difference significant only in post hoc analysis; T cells producing tumour necrosis factor alpha fell	Double-blind placebo-controlled phase 2 pilot	19877047
DEN-181 (collagen II peptide with calcitriol, liposomal)	17 ACPA positive rheumatoid arthritis patients on methotrexate	Safety, pharmacokinetics, autoreactive T cells	Tolerated; Cit-Vim-specific T cells fell at medium and high doses	Double-blind single ascending dose phase 1	36278483
Semaglutide	407 adults with obesity (BMI 30 plus) and moderate knee osteoarthritis	WOMAC pain and body weight at week 68	Pain minus 41.7 against minus 27.5 points; weight minus 13.7 against minus 3.2 percent	Randomised double-blind placebo-controlled	39476339
Semaglutide and other antidiabetic drugs	Nine randomised trials in obesity with knee osteoarthritis	WOMAC pain against usual care	Metformin minus 1.13 (95 percent CI minus 1.48 to minus 0.78); semaglutide minus 0.90 (minus 1.48 to minus 0.32)	Network meta-analysis	40325308
Oral salmon calcitonin	1,176 and 1,030 adults with painful knee osteoarthritis, Kellgren-Lawrence 2 to 3	Joint space width and WOMAC over 24 months	Joint space narrowing not significant in either trial; authors reported no reproducible clinical benefit	Two randomised placebo-controlled phase 3 trials	25582279
Collagen peptide (oral)	507 knee osteoarthritis patients, four randomised trials	Pain against placebo	Standardised mean difference minus 0.58 (95 percent CI minus 0.98 to minus 0.18); all four trials rated high risk of bias	Meta-analysis	37717022
Sprifermin (recombinant FGF-18, intra-articular)	549 adults aged 40 to 85 with symptomatic radiographic knee osteoarthritis, Kellgren-Lawrence 2 or 3	Femorotibial cartilage thickness on MRI at 2 years	Plus 0.05 mm (95 percent CI 0.03 to 0.07) at 100 microgram every 6 months, called of uncertain clinical importance	Randomised placebo-controlled, five arms	31593273
Teriparatide	50 adults after pertrochanteric hip fracture fixation	Radiographic bone union time	7.44 against 10.56 weeks, p = 0.0083; hip score and walking tests improved in both arms	Randomised double-blind placebo-controlled	40461584
Teriparatide	50 knee osteoarthritis patients having total knee replacement	Prosthesis migration, 12 to 24 months, radiostereometry	0.14 against 0.13 mm; 95 percent CI for the difference minus 0.03 to 0.04 mm	Randomised, blinded evaluation, untreated control	28287044
Teriparatide	50 adults after arthroscopic rotator cuff repair, 43 analysed	ASES shoulder score at 1 year, MRI tendon integrity	ASES p = 0.87; retear 8.7 against 10 percent, p = 0.94	Triple-blind randomised placebo-controlled	40978001
Teriparatide	31 patients after repair of cuff tears above 2 cm, propensity-matched controls	MRI retear rate at 1 year or later	16 against 33.9 percent, p = 0.04; motion and function did not separate	Propensity-matched, level III	30857903
Hydrolyzed collagen peptide device (intra-articular)	47 hip arthroscopy patients with impingement, 23 device, 24 cortisone	HOOS function and VAS pain, 1 and 6 months	Differences between the two treatments not significant	Blind randomised comparative, level III	39896095
BPC-157 (intra-articular)	17 knee pain patients at one clinic, 16 reached by telephone	Patient-recalled relief 6 to 12 months after injection	14 of 16 reported relief, 11 of the 12 given BPC-157 alone	Retrospective chart review, telephone survey	34324435
BPC-157	Literature to June 2024; 544 articles screened, 36 included	Mechanism, musculoskeletal outcomes, metabolism, safety	35 of the 36 were preclinical and 1 clinical; half-life under 30 minutes	Systematic review, level IV and V studies	40756949
BPC-157 and TB-500 (synthetic thymosin beta-4)	32 rats after Achilles transection and repair, four groups of eight	Maximum load to failure, Bonar and Movin scores, 4 weeks	TB-500 significant on load (p below 0.05), Bonar (p = 0.016), Movin (p = 0.017); BPC-157 lower without significance	Randomised animal study	42542926
Thymosin beta-4 (measured, not administered)	216 knee osteoarthritis patients and 152 healthy controls	Serum and synovial thymosin beta-4 against Kellgren-Lawrence grade	Higher than controls, correlated with radiographic severity	Observational case-control	23816466
KPV (alpha-MSH 11-13) within a melanocortin panel	Human C-20/A4 chondrocyte line with lipopolysaccharide	Viability, IL-6, IL-8, MMP-1, MMP-3, MMP-13	Viability loss attenuated by MC1 agonist BMS-470539 and MC3 agonists PG-990 and DTrp8-gamma-MSH	In vitro cell culture	32004526

Rheumatoid arthritis

Rheumatoid arthritis is an immune disease of the joint lining, and these trials ran on top of standard therapy. The corticotropin trial treated everyone openly for 12 weeks, then randomised only those who reached low disease activity, so its week 24 figure answers a maintenance question (PMID 32185745).

Tolerising approaches tried teaching the immune system to accept a self antigen: dnaJP1 in 160 patients selected for reactivity to it (PMID 19877047), and DEN-181, a collagen II peptide with calcitriol in liposomes, in 17 ACPA positive patients on methotrexate, where the endpoints were safety and T cell behaviour (PMID 36278483). Background sits in the inflammation research guide.

Knee osteoarthritis

A 68-week randomised trial tested a compound developed for weight rather than for joints, in people with a mean body mass index of 40.3 (PMID 39476339). Whether the pain change follows from the joint or from the load on it is left open by that design, and the network meta-analysis supplies comparison figures (PMID 40325308). Side effects sit in the GLP-1 side effects guide and the semaglutide profile.

Oral salmon calcitonin was taken to a structural endpoint: two 24-month phase 3 trials measured joint space width on X-ray alongside WOMAC (PMID 25582279). For oral collagen peptides the pooled pain estimate arrives with a high risk of bias rating on every trial feeding it (PMID 37717022). The collagen peptides guide and the joint pain supplements review set those beside omega-3 and curcumin.

Measuring cartilage

Cartilage thickness was measured directly in the trial of sprifermin, a recombinant FGF-18 protein injected into the knee across five arms in 549 patients, on quantitative MRI (PMID 31593273). Its authors described the 0.05 mm difference as statistically significant and of uncertain clinical importance, and the doses section carries what that arm received.

After joint surgery

Teriparatide, a 34 amino acid fragment of parathyroid hormone, has been through several surgical studies that disagree. Bone healing time after hip fracture fixation moved, while the function tests in the same trial improved in both arms without separating (PMID 40461584). Prosthesis migration after knee replacement did not separate (PMID 28287044).

The triple-blind randomised trial after rotator cuff repair found the arms alike on shoulder score and retear rate (PMID 40978001), while the propensity-matched study of the same question reported a retear difference (PMID 30857903). A hydrolysed collagen peptide device was compared against cortisone at the end of hip arthroscopy rather than against an inactive injection (PMID 39896095), and comparable to cortisone answers a narrower question than a placebo-controlled trial would.

BPC-157, TB-500 and KPV

A 2021 BPC-157 knee report is a chart review whose outcome was patient recall by telephone (PMID 34324435), and a 2025 systematic review to June 2024 included 36 studies, 35 of them preclinical (PMID 40756949). The profile is at BPC-157.

For thymosin beta-4, labelled TB-500 in its synthetic form, a human joint study measured the peptide in patients rather than administering it (PMID 23816466). In the four-week rat Achilles study, TB-500 reached significance on the biomechanical and histology measures, BPC-157 did not on totals, and the combination added nothing over either alone (PMID 42542926). That runs against the stacking idea in the Wolverine stack guide, and it remains a rat tendon.

KPV, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, appears through a chondrocyte cell culture experiment in which significant effects were reported for the receptor-selective agonists beside it (PMID 32004526). A chondrocyte in a dish is a mechanism experiment.

Doses used in these trials

What each named trial administered to its own enrolled population under supervision.

The 68-week knee osteoarthritis trial administered:

Semaglutide 2.4 mg subcutaneously once weekly for 68 weeks (Bliddal et al., N Engl J Med 2024, PMID 39476339).